Core Viewpoint - Teleflex Incorporated has announced a definitive agreement to acquire the Vascular Intervention business of BIOTRONIK SE & Co. KG for approximately €760 million, aiming to enhance its presence in the interventional cardiology and peripheral vascular market, which is estimated to be worth $10 billion [1][2]. Group 1: Acquisition Details - The acquisition is expected to close by the end of the third quarter of 2025, subject to customary closing conditions and regulatory approvals [1]. - The acquired business will expand Teleflex's portfolio to include a range of vascular intervention devices, with 75% of the acquired revenues coming from coronary interventions and 25% from peripheral procedures [2][3]. - Key products in the acquired portfolio include drug-coated balloons, drug-eluting stents, and various stent types for both coronary and peripheral interventions [2]. Group 2: Strategic Implications - The acquisition is anticipated to significantly enhance Teleflex's global presence in the cath lab and improve patient care through an expanded suite of innovative technologies [2]. - The integration of BIOTRONIK's products is expected to complement Teleflex's existing complex percutaneous coronary intervention (PCI) platform and diversify its geographic revenue mix, with 50% of the acquired revenues generated in EMEA [2][3]. - Teleflex plans to leverage its established education and clinical platforms to further enhance the offerings to cardiac and peripheral care specialists [4][5]. Group 3: Financial Outlook - The acquired products are projected to generate approximately €91 million in revenues in the fourth quarter of 2025, with expected constant currency revenue growth of 6% or better starting in 2026 [6][7]. - The transaction is expected to be approximately $0.10 accretive to Teleflex's adjusted earnings per share in the first year of ownership, with increasing accretion thereafter [8]. - Teleflex intends to finance the acquisition through a new term loan, revolving borrowings, and cash on hand, while also entering into foreign exchange derivative contracts to hedge against currency exposure [9][8].

WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it has entered into a definitive agreement to acquire substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG for an estimated cash payment on closing of approximately €760 million, less certain adjustments as provided in the purchase agreement including certain working capital not transferring and other customary adjustments. The acquisi ...

WAYNE, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX), will be presenting at the Raymond James & Associates 46th Annual Institutional Investors Conference at the JW Marriott Grande Lakes, Orlando, FL, on Tuesday, March 4, 2025, at 3:25 p.m. (ET). A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex IncorporatedAs a global pr ...

WAYNE, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE:TFX), will be presenting at the Raymond James & Associates 46th Annual Institutional Investors Conference at the JW Marriott Grande Lakes, Orlando, FL, on Tuesday, March 4, 2025, at 3:25 p.m. (ET). A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex IncorporatedAs a global pro ...

WAYNE, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 27, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beg ...

Including market leading Arrow™ CVCs and Arterial CathetersWAYNE, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has been awarded a contract by Vizient, Inc., the largest provider-driven healthcare performance improvement company in the U.S. The agreement, effective January 1, 2025, covers the supply of Teleflex’s Central Venous Access Catheters and Arterial Catheters. Vizient provides solutions and services tha ...

WAYNE, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE:TFX), is scheduled to speak at the 43rd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis in San Francisco, California, on Tuesday, January 14, 2025, at 5:15 p.m. (PT). A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex Incorporated ...

Teleflex’s (TFX) broad Vascular Access portfolio is poised to continue to win shares through its category leadership in Central Venous Catheters (CVC), midlines and new launches. The company’s expansion efforts into Asia bring promising long-term growth prospects. The Interventional arm is also driving solid growth through its key drivers, which is highly promising.  Meanwhile, the adverse impact of macroeconomic challenges and the competitive landscape remains a concern for Teleflex.In the past year, this ...

Teleflex (TFX) recently launched its new Pressure Injectable Arrowg+ard Blue Plus MSB Procedure Kit in Europe, the Middle East and Africa (EMEA). This is regarded as a significant addition to the company’s market-leading portfolio of Centrally-Inserted Central Catheters.The Kit also features the Arrowg+ard Blue Plus CVC (central venous catheter), the only full-spectrum antimicrobial CVC that protects against gram-positive and gram-negative bacteria and fungi — the key infectious pathogens responsible for CL ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zack ...